^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

ILT-3 inhibitor

11d
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
P1, N=230, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Feb 2025 --> Jun 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
2ms
Enrollment closed
|
Keytruda (pembrolizumab) • NGM438
5ms
BND-35-001: A Study of BND-35 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=280, Recruiting, Biond Biologics | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Opdivo (nivolumab) • Erbitux (cetuximab)
5ms
IO-202-CL-001: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML (clinicaltrials.gov)
P1, N=106, Active, not recruiting, Immune-Onc Therapeutics | Recruiting --> Active, not recruiting
Enrollment closed
|
LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
|
Venclexta (venetoclax) • azacitidine • IO-202
7ms
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors (clinicaltrials.gov)
P1, N=22, Completed, Immune-Onc Therapeutics | Active, not recruiting --> Completed | N=200 --> 22
Trial completion • Enrollment change • Combination therapy • Metastases
|
LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
|
Keytruda (pembrolizumab) • IO-202
7ms
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma. (PubMed, Haematologica)
In conclusion, our study elucidates that LILRB4 is an ideal biomarker and promising immunotherapy target for high-risk MM. LILRB4-STAR-T cell immunotherapy is promising against tumor cells and immunosuppressive tumor microenvironment in MM.
Journal • IO biomarker • Tumor cell
|
LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
|
YTS104
7ms
New P1 trial
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD163 (CD163 Molecule) • GZMB (Granzyme B)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
10ms
Phase classification • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
10ms
New P1 trial • Combination therapy • Metastases
|
Opdivo (nivolumab) • Erbitux (cetuximab)
10ms
KEYNOTE-E13: Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=130, Recruiting, NGM Biopharmaceuticals, Inc | N=79 --> 130 | Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Feb 2024 --> Jul 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • NGM438
12ms
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML (clinicaltrials.gov)
P1, N=106, Recruiting, Immune-Onc Therapeutics | Trial completion date: May 2025 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Jan 2026
Trial completion date • Trial primary completion date
|
LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
|
Venclexta (venetoclax) • azacitidine • IO-202
12ms
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
P1, N=12, Terminated, Merck Sharp & Dohme LLC | N=35 --> 12 | Active, not recruiting --> Terminated; Business Reasons
Enrollment change • Trial termination
|
MK-0482
1year
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
P1, N=35, Active, not recruiting, Merck Sharp & Dohme LLC | Phase classification: P1b --> P1 | Trial completion date: Aug 2025 --> Dec 2023 | Trial primary completion date: Aug 2025 --> Dec 2023
Phase classification • Trial completion date • Trial primary completion date
|
MK-0482
1year
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors (clinicaltrials.gov)
P1, N=200, Active, not recruiting, Immune-Onc Therapeutics | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • IO-202
over1year
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=8, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital
New P1 trial
|
LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
|
cyclophosphamide • YTS104
over1year
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors (clinicaltrials.gov)
P1, N=200, Recruiting, Immune-Onc Therapeutics | Trial primary completion date: Apr 2023 --> Apr 2024
Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • IO-202
over1year
Enrollment closed • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
over1year
A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4 MAB) IN ACUTE MYELOID LEUKEMIA (AML) WITH MONOCYTIC DIFFERENTIATION AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS (EHA 2023)
In combination therapy, 1 AML patient with high LILRB4 expression who was refractory to azacitidine and venetoclax based combination therapy achieved CR, ongoing at 7+ months. IO-202 is safe and well tolerated as monotherapy and in combination with AZA. Encouraging responses, including monotherapy activity, ongoing CR in an AML patient with high LILRB4 expression, and PR and Optimal Marrow Response in CMML patients, were observed. PD biomarker data supported proposed MOA.
Clinical • P1 data
|
APOE (Apolipoprotein E) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
|
PGR expression • LILRB4 overexpression
|
Venclexta (venetoclax) • azacitidine • IO-202
over1year
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
P1b, N=35, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2025
Trial completion date • Trial primary completion date
|
MK-0482
almost2years
Enrollment change
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
2years
Preclinical Characterization of NGM936, a Novel Bispecific T Cell Engager Targeting ILT3 for the Treatment of Acute Myeloid Leukemia with Monocytic Differentiation (ASH 2022)
In both whole blood cytokine release assays and in TDCC assays in which cytokine secretion was measured after target engagement, induction of TNF-α, IL-6, IFN-γ, and IL-2 by NGM936 was considerably lower than that induced by a vibecotamab biosimilar (CD123 x CD3). Finally, NGM936 induced a dose-dependent depletion of circulating tumor cells in a xenograft model in which irradiated, immunodeficient NSG mice were engrafted with human PBMCs and human ILT3+ AML cells. NGM936 thus represents a promising new treatment strategy for monocytic AML, with the potential to eliminate monocytic leukemia cells while minimizing the myelotoxicity associated with ablation of healthy bone marrow.
Preclinical
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD34 (CD34 molecule) • IL2 (Interleukin 2)
|
vibecotamab (XmAb14045) • NGM936
2years
A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma (ASH 2022)
Our work represents the first evidence and rationale for clinical development of NGM936 surrogate antibody an ILT3-targeted immunotherapy as a viable therapeutic approach for MM cell killing. These data suggest that targeting ILT3 is an effective and safe therapeutic approach in MM.
IO biomarker
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
Chr t(14;16)
|
NGM936
over2years
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
P1b, N=230, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
almost3years
Enrollment change • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
almost3years
Enrollment change
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • 5-fluorouracil • MK-0482 • MK-4830 • dazostinag (TAK-676)
almost3years
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
P1b, N=230, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
almost3years
Protein Arginine Methyltransferase 5 Promotes the Migration of AML Cells by Regulating the Expression of Leukocyte Immunoglobulin-Like Receptor B4. (PubMed, Biomed Res Int)
Taken together, PRMT5 plays an important role in the invasion of AML, which acts via regulating the expression of LILRB4. PRMT5 could act as a potential therapeutic candidate for AML.
Journal
|
PRMT5 (Protein Arginine Methyltransferase 5)
3years
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia. (PubMed, Curr Hematol Malig Rep)
Limited data suggest that short-lived remissions can be obtained employing CPX-351 or venetoclax-based lower intensity combination therapy. Promising future strategies include repurposing cladribine, exploiting the supportive role of dendritic cell subsets with anti-CD123 therapies, MCL-1 inhibition, dual MEK/PLK1 inhibition, FLT3 inhibition in RAS-mutated and CBL-mutated subsets, and immune therapies targeting novel immune checkpoint molecules such as the leukocyte immunoglobulin-like receptor B4 (LILRB4), an immune-modulatory transmembrane protein restrictively expressed on monocytic cells. The successful management of an entity as unique as CMML-BP will require a cooperative, concerted effort to design and conduct clinical trials dedicated to this rare form of sAML.
Review • Journal
|
FLT3 (Fms-related tyrosine kinase 3) • CD123 (Interleukin 3 Receptor Subunit Alpha)
|
CBL mutation
|
Venclexta (venetoclax) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • cladribine
3years
Aryl Hydrocarbon Receptor (AHR) Gene Expression in AML Is Associated with FLT3-ITD+ AML and HLA-E Induced Immune Resistance Reversed By Ik-364 (ASH 2021)
The highest and lowest 10% expression levels of AHR in all samples in Beat AML were evaluated for mutation profiles. Ranking the top 18 mutations based on frequency we found an enrichment of FLT3 mutations in the high AHR expression group compared to the lower expression group (Figure 1A). ELN risk did not correlate with AHR expression however FAB classification M0/M1 and M4/M5 monocytic subtypes had higher AHR expression than M3 FAB subtype (Figure 2A).
PD(L)-1 Biomarker • IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CASP3 (Caspase 3) • CD14 (CD14 Molecule) • MAFB (MAF BZIP Transcription Factor B) • AHR (Aryl hydrocarbon receptor) • CASP7 (Caspase 7) • CD86 (CD86 Molecule)
|
FLT3-ITD mutation • FLT3 mutation • FLT3-ITD expression • AHR expression
3years
Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting (ASH 2021)
CCR1, IL12RB1, LILRB4 and SEMA4A were upregulated by the treatment with Bortezomib or Venetoclax that conversely, decreased BCMA expression in MM U266 cells. This study suggests the contribution of an altered MM surfaceome to disease development and may lead to potential novel immunotherapeutic approaches for high-risk MM. References Perna F et al., Cancer Cell 2017 Perna F. Molecular Therapy 2021 Dong C et al., in press Oncogene 2021
IO biomarker
|
LY9 (Lymphocyte Antigen 9) • ITGA4 (Integrin, alpha 4) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1)
|
Chr t(4;14) • Chr t(14;16)
|
Venclexta (venetoclax) • bortezomib
over3years
Molecular Examination of Differentially Expressed Genes in the Brains of Experimental Autoimmune Encephalomyelitis Mice Post Herceptin Treatment. (PubMed, J Inflamm Res)
Except for the mRNA levels of Cd74 and Clec7a which were increased at HCS when Herceptin was used in both prophylactic and therapeutic regimens, the levels of other described mRNAs were reduced. These novel findings show that Herceptin ameliorates the clinical score in EAE mice and are the first to investigate in detail the differential gene expression post-treatment with the drug.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD74 (CD74 Molecule) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CLEC7A (C-Type Lectin Domain Containing 7A) • HSPB1 (Heat shock 27kDa protein 1)
|
HER-2 expression
|
Herceptin (trastuzumab)
over3years
Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma. (PubMed, Mol Immunol)
This is the first systemically examination of the LILRB family expression on a variety of immune cells from both peripheral blood and microenvironment in HCC patients. The specific increasing expression of LILRB on immune cells may regulate innate and adaptive immune and impact on HCC progression. Our findings justify further investigation of LILRB function in HCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
CD8 expression
over3years
Blockade of checkpoint ILT3/LILRB4/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB/Yaa mice. (PubMed, Int Immunol)
Blockade of B4-FN binding such as with B4 antibodies or a recombinant FN30-Fc fusion protein paradoxically ameliorated autoimmune disease in lupus-prone BXSB/Yaa mice. These unexpected nature of the B4-FN checkpoint in autoimmunity is discussed, referring to its potential role in tumor immunity.
Preclinical • Journal
|
FN1 (Fibronectin 1)
over3years
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. (PubMed, J Exp Med)
LILRB4-/- genotype or LILRB4 blockade increased tumor immune infiltrates and the effector (Teff) to regulatory (Treg) T cell ratio and modulated phenotypes of TAMs toward less suppressive, CD4+ T cells to Th1 effector, and CD8+ T cells to less exhausted. These findings reveal that LILRB4 strongly suppresses tumor immunity in TME and that alleviating that suppression provides antitumor efficacy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
almost4years
ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells. (PubMed, Mol Cancer Res)
Finally, in combination with anti-programmed cell death protein 1 (PD1), ILT3 blockade enhanced T cell activation as assessed by IFN-γ secretion. Implications: These results suggest that ILT3 expressed on M-MDSCs has a role in inducing immunosuppression in cancer and that antagonism of ILT3 may be useful to reverse the immunosuppressive function of M-MDSCs and enhance the efficacy of immune checkpoint inhibitors.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD33 (CD33 Molecule) • ITGAM (Integrin, alpha M)
|
IFNG expression • M-MDSCs
almost4years
Suppression of Experimental Autoimmune Encephalomyelitis by ILT3.Fc. (PubMed, J Immunol)
These results indicate that inhibition of Th1 and Th17 development provides effective suppression of EAE and suggests the feasibility of a clinical approach based on the use of ILT3.Fc for treatment of MS. Furthermore, our results open the way to further studies on the effect of the human ILT3.Fc protein in murine experimental models of autoimmunity and cancer.
Journal
|
IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
4years
[VIRTUAL] A First-in-Human (FIH) Phase 1 Study of the Anti-LILRB4 Antibody IO-202 in Relapsed/Refractory (R/R) Myelomonocytic and Monocytic Acute Myeloid Leukemia (AML) and R/R Chronic Myelomonocytic Leukemia (CMML) (ASH 2020)
Major exclusion criteria include: 1) HSCT within 60 days, on calcineurin inhibitors, or chronic GVHD; 2) chemotherapy, radiotherapy, or investigational agents within 7 days; 3) significant cardiac disease; 4) active infection; 5) uncontrolled CNS leukemia; and 6) hyperleukocytosis ( > 25 x 109/L, although hydroxyurea is permitted). If there is a >80% probability of DLTs being > 20%, the study will be paused to further evaluate the safety findings. A planned protocol amendment will evaluate combination therapies with IO-202, including IO-202 + azacitidine.
P1 data
|
CD8 (cluster of differentiation 8)
|
azacitidine • hydroxyurea • IO-202
over4years
Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. (PubMed, Cytometry B Clin Cytom)
The co-expression of LILRB1/LILRB4 outperformed other myelomonocytic markers as a highly sensitive and specific marker for monocytes at all stages of maturation and could reliably distinguish M-AML from NM-AML. LILRB4 additionally represents a novel therapeutic target for treating M-AML.
Journal
|
CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD36 (thrombospondin receptor) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M)
over4years
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. (PubMed, Cancer Cell)
FTO inhibition sensitizes leukemia cells to T cell cytotoxicity and overcomes hypomethylating agent-induced immune evasion. Our study demonstrates that FTO plays critical roles in cancer stem cell self-renewal and immune evasion and highlights the broad potential of targeting FTO for cancer therapy.
Clinical • Journal
|
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
almost5years
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. (PubMed, Leuk Lymphoma)
Given current modest results with immunotherapy in myeloid malignancies, further investigation of LILRB4 as an immune checkpoint inhibitor target is needed. With the positive correlation between LILRB4 and CTLA-4 expression, combining anti-LILRB4 and anti-CTLA-4 agents may be a novel therapeutic approach in myeloid malignancies that warrants larger studies.
Journal • PD(L)-1 Biomarker
|
PD-1 (Programmed cell death 1)